An open-label study was carried out in 2016 in the UK to analyze the feasibility, safety and efficacy of psilocybin in managing individuals with unipolar treatment-resistant depression with promising effects; although the review was small and concerned only twelve individuals, 7 of those clients fulfilled official standards for remission one partic